: CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com CONMED Corporation Announces Second Quarter 2016 Financial Results Utica, New York

CONMED Corporation Announces Second Quarter

2016 Financial Results

Utica, New York, July 27, 2016 --- CONMED

Corporation (Nasdaq: CNMD) today announced financial results for the second quarter ended June 30, 2016.

Second Quarter 2016 Highlights

"We are encouraged by several trends

in our second quarter results, highlighted by the strong contribution from the AirSeal System, a return to constant

currency growth in all three of our product categories internationally, and gross margin expansion," commented Curt R. Hartman,

CONMED's President and Chief Executive Officer. "However, these positives were offset by our domestic organic performance,

which was again below our expectations. Looking to the remainder of the year, we will continue to invest in innovative products,

to focus on operating efficiencies, and to pursue our strategic initiatives to position the Company for continued improvement

For the quarter ended June 30, 2016, domestic

sales, which represented 51.0% of total revenue, increased 10.9% as strong growth in General Surgery was partially offset by declines

in Orthopedics and Visualization. The SurgiQuest acquisition contributed to 26.5% year-over-year growth in the U.S. General Surgery

business. International sales, which represented 49.0% of total revenue, increased 2.9% compared to the second quarter of 2015

on a reported basis. Foreign currency exchange rates, including the effects of the FX hedging program, had a negative impact of

$4.3 million on second quarter sales. In constant currency, international sales increased 7.5% versus the prior-year period.

For the quarter ended June 30, 2016, reported

net earnings totaled $2.9 million, compared to reported net earnings of $7.5 million a year ago. Reported diluted net earnings

per share were $0.10 in the quarter, compared to reported diluted net earnings per share of $0.27 in the prior-year period. Reported

net earnings for 2016 include business acquisition and restructuring costs, and reported net earnings for 2015 include restructuring

costs. The effect of each of these items on reported net earnings and reported diluted net earnings per share appears in the reconciliation

of GAAP to non-GAAP measures below.

As previously announced, the Company is excluding

after-tax costs of special items including acquisitions, restructuring, and debt refinancing, as well as amortization of intangible

assets, net of tax, from its adjusted diluted net earnings per share. Excluding the impact of these items, adjusted net earnings(2)

of $13.2 million increased 9.8% year over year and adjusted diluted net earnings per share(1) of $0.47 increased 9.3%

year over year. The increase in adjusted net earnings was largely attributable to improved gross margin and a lower tax rate during

the quarter, partially offset by higher selling and administrative expenses and the unfavorable impact of foreign exchange rates.

Based on weaker-than-expected organic sales

performance to date, the Company is reducing its 2016 constant currency organic sales growth estimate to -1% to 1%, compared to

the previous range of 1% to 3%. Also, based on foreign currency exchange rates as of July 22, 2016, the Company is updating the

anticipated negative impact of foreign exchange for the year to $17 to $19 million, compared to the previous range of $13 to $15

million. Additionally, due to stronger-than-expected year-to-date performance of AirSeal , the Company is increasing

its sales forecast related to the SurgiQuest acquisition to $62 to $67 million, compared to the previous range of $55 to $60 million.

As a result, the Company is revising its 2016

guidance for reported sales and adjusted diluted net earnings per share. The Company now forecasts 2016 reported sales in the range

of $757 to $767 million, which represents growth of 5.3% to 6.7% over reported 2015 revenue of $719 million, compared to the previous

range of $768 to $778 million. Based on the Company's revised 2016 reported sales estimate range, adjusted diluted net earnings

per share are now expected to be in the range of $1.83 to $1.93, compared to the previous range of $1.95 to $2.05. The adjusted

diluted net earnings per share estimates for 2016 exclude the cost of special items including acquisition costs, restructuring

costs, and debt refinancing, which are now estimated in the range of $21 to $23 million, net of tax, compared to the previous range

of $18 to $20 million, and amortization of intangible assets, which are still estimated in the range of $12 to $14 million, net

Supplemental Financial Disclosures

(1) A reconciliation of reported

diluted net earnings per share to adjusted diluted net earnings per share, a non-GAAP financial measure, appears below.

(2) A reconciliation of reported

net earnings to adjusted net earnings, a non-GAAP financial measure, appears below.

In conjunction with this earnings press release,

CONMED has prepared supplemental financial disclosures which are available on the home page of the "Investors - Financial

Reports" section of the Company's website at www.conmed.com.

The Company's management will host a

conference call today at 4:30 p.m. ET to discuss its second quarter 2016 results.

To participate in the conference call, dial

877-573-5235 (domestic) or 503-406-4448 (international) and enter the passcode 45094961.

This conference call will also be webcast

and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay

of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available

from 7:30 p.m. ET on Wednesday, July 27, 2016, until 11:59 p.m. ET on Wednesday, August 10, 2016. To hear this recording, dial

855-859-2056 (domestic) or 404-537-3406 (international) and enter the passcode 45094961.

About CONMED Corporation

CONMED is a medical technology company that

provides surgical devices and equipment for minimally invasive procedures. The Company's products are used by surgeons and

physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology.

The Company distributes its products worldwide from several manufacturing locations. CONMED has a direct selling presence in 17

countries, and international sales constitute approximately 50% of the Company's total sales. Headquartered in Utica, New

York, the Company employs approximately 3,400 people. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release and today's conference

call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties,

which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements

herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause

actual results to differ materially from those in the forward-looking statements may include, but are not limited to, the risks

factors discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015. Any and all forward-looking

statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to

the Company's performance on a going-forward basis. The Company believes that all forward-looking statements made by it have

a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in

the forward-looking statements will actually occur or prove to be correct.

Supplemental Information - Reconciliation

of GAAP to Non-GAAP Financial Measures

The Company supplements the reporting of its

financial information determined under accounting principles generally accepted in the United States (GAAP) with certain non-GAAP

financial measures, including percentage sales growth in constant currency; adjusted gross profit; cost of sales excluding specified

items; adjusted selling and administrative expenses; adjusted operating income; adjusted income tax expense; adjusted effective

income tax rate; adjusted net earnings and adjusted diluted net earnings per share (EPS). The Company believes that these non-GAAP

measures provide meaningful information to assist investors and shareholders in understanding our financial results and assessing

our prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures

described above are important indicators of our operations because they exclude items that may not be indicative of, or are unrelated

to, our core operating results and provide a baseline for analyzing trends in the Company's underlying business. Further,

the presentation of EBITDA is a non-GAAP measurement that management considers useful for measuring aspects of the Company's

cash flow. Management uses these non-GAAP financial measures for reviewing the operating results and analyzing potential future

business trends in connection with our budget process and bases certain management incentive compensation on these non-GAAP financial

To measure percentage sales growth in constant

currency, the Company removes the impact of changes in foreign currency exchange rates that affect the comparability and trend

of sales. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that affect

the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative

of our past and future performance and are therefore excluded to allow investors to better understand underlying operating trends.

Because non-GAAP financial measures are not